9-(6-aminohexyl)adenine | 21708-32-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 咪唑并嘧啶类
• 英文名称: 9-(6-aminohexyl)adenine
• 英文别名: 9-(6-amino-hexyl)-9H-purin-6-ylamine；9-<6-Amino-hexyl>-adenin；9-(6-Aminohexyl)purin-6-amine
• CAS: 21708-32-7
• 化学式: C₁₁H₁₈N₆
• mdl: MFCD23133776
• 分子量: 234.304
• InChiKey: PPRSJCDSXZSVHV-UHFFFAOYSA-N

物化性质

• 沸点：
  462.3±55.0 °C(Predicted)
• 密度：
  1.36±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  17
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.545
• 拓扑面积：
  95.6
• 氢给体数：
  2
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  9-(6-aminohexyl)adenine 、 N-hydroxysuccinimide ester of 4-androsten-3-one-17β-carboxylic acid 在 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 以79%的产率得到17β-[6-(6-aminopurin-9-yl)hexylcarbamoyl]androst-4-en-3-one
  参考文献：
  名称：

  Design, synthesis and evaluation of progesterone–adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux

  摘要：

  Steroidal bivalent ligands were designed on the basis of the described closer proximity of the ATP-site and the putative steroid-binding site of P-glycoprotein (ABCB1). The syntheses of seven progesterone-adenine hybrids were described. Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.03.085
• 作为产物：
  描述：

  6-(Z-氨基)-1-己醇 在 偶氮二甲酸二异丙酯 、 10% Pd/C 、 氢气 、 三苯基膦 作用下， 以 四氢呋喃 、 甲醇 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 1.0h， 生成 9-(6-aminohexyl)adenine
  参考文献：
  名称：

  Progesterone–adenine hybrids as bivalent inhibitors of P-glycoprotein-mediated multidrug efflux: Design, synthesis, characterization and biological evaluation

  摘要：

  Bivalent ligands were designed on the basis of the described close proximity of the ATP-site and the putative steroid-binding site of P-glycoprotein (ABCB1). The syntheses of 19 progesterone-adenine hybrids are described. Their abilities to inhibit P-glycoprotein-mediated daunorubicin efflux in K562/R7 human leukemic cells overexpressing P-glycoprotein were evaluated versus progesterone. The hybrid with a hexamethylene linker chain showed the best inhibitory potency. The efficiency of these progesterone-adenine hybrids depends on two main factors: (i) the nature of the linker and (ii) its attachment point on the steroid skeleton. (C) 2012 Elsevier Inc. All rights reserved.

  DOI：

  10.1016/j.steroids.2012.07.010

文献信息

• [EN] NUCLEIC ACID CONJUGATES AND USES THEREOF<br/>[FR] CONJUGUÉS DE TYPE ACIDE NUCLÉIQUE ET LEURS UTILISATIONS
  申请人：TRANSLATE BIO MA INC

  公开号：WO2018013525A1

  公开（公告）日：2018-01-18

  Provided herein are conjugates comprising targeting moieties such as sugars, folates and cell-penetrating peptides, which can be used for the improved delivery of agents (e.g., nucleic acids, such as oligonucleotides or mRNAs, or other agents) to cells. The invention provides conjugates and compounds comprising targeting moieties, methods for preparing the same, and intermediates useful in their preparation. In another aspect, the present invention provides formulations (e.g., pharmaceutical compositions) comprising the targetting moiety-containing conjugates and compounds. The present invention also provides methods for delivering agents (e.g., nucleic acids such as oligonucleotides or mRNAs) to a cell, methods for treating and/or preventing a disease or condition in a subject, and methods for modulating gene expression in a cell or a subject. Further, provided herein are kits comprising the conjugates, or formulations thereof; and kits for the preparation of conjugates described herein.

  本文提供了包含靶向基团的共轭物，如糖类、叶酸和穿膜肽，可用于改善药物（例如核酸，如寡核苷酸或mRNA，或其他药物）对细胞的传递。该发明提供了包含靶向基团的共轭物和化合物，以及其制备方法和制备过程中有用的中间体。另一方面，本发明提供了包含靶向基团的共轭物和化合物的配方（例如，药物组合物）。本发明还提供了将药物（例如核酸，如寡核苷酸或mRNA）传递至细胞的方法，用于治疗和/或预防受试者疾病或状况的方法，以及用于调节细胞或受试者基因表达的方法。此外，本文提供了包含这些共轭物或其配方的试剂盒；以及用于制备本文所述共轭物的试剂盒。
• [EN] TARGETED DELIVERY TO BETA CELLS<br/>[FR] ADMINISTRATION CIBLÉE À DES CELLULES BÊTA
  申请人：CHOUDHARY AMIT

  公开号：WO2018195486A1

  公开（公告）日：2018-10-25

  The disclosure includes zinc prodrugs for targeted delivery of therapeutic, diagnostic or imaging agents to β-cells and methods of use therefor. The disclosure also includes targeted delivery of small molecules to β-cells that stabilize and activate CRISPR effector proteins comprising at least one destabilization domain, to enable CRISPR-based genome editing and transcriptional activation or repression in β-cells.

  本公开内容包括用于将治疗性、诊断性或成像剂靶向递送至β细胞的锌前药及其使用方法。本公开内容还涉及将小分子靶向递送至β细胞，这些小分子能够稳定并激活至少含有一个不稳定域的CRISPR效应蛋白，从而在β细胞中实现基于CRISPR的基因编辑和转录激活或抑制。
• Antisense modulation of MDM2 expression
  申请人：——

  公开号：US20030203862A1

  公开（公告）日：2003-10-30

  Compounds, compositions and methods are provided for inhibiting the expression of human mdm2. The compositions include antisense compounds targeted to nucleic acids encoding mdm2. Methods of using these oligonucleotides for inhibition of mdm2 expression and for treatment of diseases such as cancers associated with overexpression of mdm2 are provided.

  提供了用于抑制人类mdm2表达的化合物、组合物和方法。这些组合物包括针对编码mdm2的核酸的反义物质。提供了使用这些寡核苷酸抑制mdm2表达和治疗与mdm2过度表达相关的癌症等疾病的方法。
• Compositions and methods for treatment of hepatitis C virus-associated diseases
  申请人：——

  公开号：US20030171313A1

  公开（公告）日：2003-09-11

  Antisense oligonucleotides are provided which are complementary to and hybridizable with at least a portion of HCV RNA and which are capable of inhibiting the function of the HCV RNA. These oligonucleotides can be administered to inhibit the activity of Hepatitis C virus in vivo or in vitro. These compounds can be used either prophylactically or therapeutically to reduce the severity of diseases associated with Hepatitis C virus, and for diagnosis and detection of HCV and HCV-associated diseases. Methods of using these compounds are also disclosed.

  提供了与HCV RNA至少部分互补且可杂交的反义寡核苷酸，能够抑制HCV RNA的功能。这些寡核苷酸可以用于体内或体外抑制丙型肝炎病毒的活性。这些化合物可用于预防或治疗与丙型肝炎病毒相关的疾病的严重程度，并用于丙型肝炎病毒及相关疾病的诊断和检测。还公开了使用这些化合物的方法。
• [EN] METHODS FOR EFFICIENT DELIVERY OF THERAPEUTIC MOLECULES IN VITRO AND IN VIVO<br/>[FR] PROCÉDÉS D'ADMINISTRATION EFFICACE DE MOLÉCULES THÉRAPEUTIQUES IN VITRO ET IN VIVO
  申请人：MASSACHUSETTS EYE & EAR INFIRM

  公开号：WO2016069910A1

  公开（公告）日：2016-05-06

  Compositions are described for direct protein delivery into multiple cell types in the mammalian inner ear. The compositions are used to deliver protein(s) (such as gene editing factors) editing of genetic mutations associated with deafness or associated disorders thereof. The delivery of genome editing proteins for gene editing and correction of genetic mutations protect or restore hearing from genetic deafness. Methods of treatment include the intracellular delivery of these molecules to a specific therapeutic target.

  本文描述了一种用于在哺乳动物内耳多种细胞类型中直接传递蛋白质的组合物。这些组合物可用于传递蛋白质（如基因编辑因子），以编辑与耳聋或相关疾病相关的遗传突变。传递基因组编辑蛋白质以编辑和纠正遗传突变，可保护或恢复遗传性耳聋的听力。治疗方法包括将这些分子进行胞内传递，以达到特定的治疗目标。